ALLO - Company ID 0001737287
The table below shows Allogene Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $22.00K | $95.00K | $156.00K | $114.09M | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $150.15M | $192.30M | $242.91M | $256.39M | $220.18M | $192.99M |
| SG&A |
Allogene Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2025. That is down 100.0% from $22.00K in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $56.78M |
| $65.20M |
| $71.67M |
| $79.31M |
| $74.11M |
| $65.26M |
| Operating income | -$209.31M | -$273.20M | -$327.74M | -$335.54M | -$180.19M | -$258.24M |
| Income tax | $0.00 | $443.00K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | -$190.89M | -$257.59M | -$327.26M | -$340.41M | -$182.05M | -$316.38M |
| EPS (diluted) | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 |